28.07.2011
- Sanofi-Aventis reported a 13.2% decline in its second-quarter business net income to €2.15 billion from €2.48 billion last year. Business earnings per share were €1.64, down 13.7%...
14.06.2011
- Biotech deals in the $1 billion to $5 billion range are likely to be a sweet spot for drug companies looking to bolster their pipelines through M&A in an increasingly tough...
11.04.2011
- Sanofi-Aventis said it has completed its takeover of U.S. biotechnology company Genzyme. The companies agreed in February on a deal worth about $20.1 billion. The acquisition gives...
04.04.2011
- French drugmaker Sanofi-Aventis completed its improved $20.1 billion offer for Genzyme allowing it to begin merging the U.S. biotech into its business and add rare diseases to its...
30.03.2011
- Certificates related to Sanofi-Aventis's $20.1 billion acquisition of U.S. biotech firm Genzyme could begin trading on Nasdaq as soon as April 4, depending on the outcome of its...
18.03.2011
- U.S. biotech company Genzyme said on Thursday it planned joint research projects with Russian high-tech centre ChemRar, joining a growing number of global drugmakers seeking to...
08.03.2011
- Genzyme Chief Executive Henri Termeer is set to walk away with nearly $160 million when the sale of his company to French drugmaker Sanofi-Aventis is final - and stands to earn...
17.02.2011
- French drugmaker Sanofi-Aventis SA agreed to buy Genzyme Corp with a sweetened $20.1 billion cash offer, plus payments tied to the success of the U.S. biotech group's drugs, the...
